Qorvo's declining ROCE and stagnant capital employed may suggest a mature business facing new competition or smaller margins. Despite concerning fundamentals, the stock's strong performance with a 63% return over the last five years indicates investor optimism. However, these trends may not bode well for long-term performance.
The growth outlook of Qorvo, coupled with its current undervaluation, makes it a potential buy. The undervaluation is attributed not only to its future expectations but also its financial health.
Qorvo executives express confidence in Luxshare's manufacturing competency and anticipate the partnership will help reduce capital intensity, support long-term gross margin objectives, and ensure continuity for their customers in China.
Morning Movers Gapping up $開利全球(CARR.US)$Shares popped nearly 6% following the announcement that Carrier agreed to sell its Global Access Solutions Business to Honeywell for $4.95 billion in cash.$霍尼韋爾(HON.US)$'s stock slipped 2.4%. $第一太陽能(FSLR.US)$The solar stock rallied 3.2% after being upgraded to overweight from equal weight by Morgan Stanley. The bank said it sees a number of drivers that can pus...
Qorvo's declining share price and EPS loss depict dwindling investor trust. However, recent sell-off might be a chance considering a long-term growth trend.
Despite the revenue contraction and gross margin decrease, Qorvo's performance is considered strong, with better-than-expected results and strong improvement in inventory levels. However, considering Qorvo's valuation and recent quarter changes, further research is suggested before investing.
Pre-Market Stock Movers Gapping up $Moderna(MRNA.US)$ (Shares added 1.6% after the biotech company released its second-quarter results. Despite posting a quarterly loss and drop in revenue, Moderna raised its full-year outlook for its Covid vaccine, its only marketable product.) $Qorvo(QRVO.US)$ (The stock rallied 6.8% after the company beat analyst expectations on top and bottom lines in the second quarter. Manage...
Qorvo股票討論區
2015年上市,主要做射頻和電源半導體業務,51%的市場在美國,當前價格112.17。
5年來營收前4年增長,2023年萎縮23.2%,平均增速3.7%,營業利潤2022年達到高點後在2023年受毛利率大幅下滑和費用增長影響大幅萎縮85.1%,淨利潤萎縮到1億。2023年利息費用0.68億。毛利率前4年從38.7%提升到49.2%,2023年大幅下滑到36.3%。
2024前3季度營收萎縮3.7%,營業利潤大幅萎縮83.4%,淨利潤轉爲虧損0.73億。
目前市盈率112,市盈率TTM虧損,5年平均淨利4.7億對應市盈率爲23,按週期股來看估值也不低,暫時缺乏吸引力。
Gapping up
$開利全球(CARR.US)$ Shares popped nearly 6% following the announcement that Carrier agreed to sell its Global Access Solutions Business to Honeywell for $4.95 billion in cash. $霍尼韋爾(HON.US)$ 's stock slipped 2.4%.
$第一太陽能(FSLR.US)$ The solar stock rallied 3.2% after being upgraded to overweight from equal weight by Morgan Stanley. The bank said it sees a number of drivers that can pus...
$凌雲半導體(CRUS.US)$ Kioxia Japan $德州儀器(TXN.US)$ $恩智浦(NXPI.US)$ $博通(AVGO.US)$ Skhynix Korea $RENESAS ELECTRONICS CORP(RNECF.US)$ $意法半導體(STM.US)$ Bosch $思佳訊(SWKS.US)$ $高通(QCOM.US)$ $Qorvo(QRVO.US)$
Gapping up
$Moderna(MRNA.US)$
(Shares added 1.6% after the biotech company released its second-quarter results. Despite posting a quarterly loss and drop in revenue, Moderna raised its full-year outlook for its Covid vaccine, its only marketable product.)
$Qorvo(QRVO.US)$
(The stock rallied 6.8% after the company beat analyst expectations on top and bottom lines in the second quarter. Manage...
暫無評論